How much to invest in glycemic control of a patient with diabetes mellitus type 2? A constant dilemma for the Brazilian Public Health System (SUS)
Diabetes mellitus type 2 (DM2) affects millions of people worldwide and causes several complications for the patient, consuming large sums of financial resources from the health services. This study aims to estimate the financial investment of DM2 treatment for glycemic control of the patient, from...
Main Authors: | Ana Carolina de Oliveira Gonçalves, Maurilio de Souza Cazarim, Cristina Sanches, Leonardo Régis Leira Pereira, André de Oliveira Baldoni |
---|---|
Format: | Article |
Language: | English |
Published: |
Universidade de São Paulo
|
Series: | Brazilian Journal of Pharmaceutical Sciences |
Subjects: | |
Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502019000100522&lng=en&tlng=en |
Similar Items
-
Pharmacoeconomics of dapagliflozin in patients with type 2 diabetes mellitus with inadequate glycemic control
by: S. K. Zyryanov, et al.
Published: (2018-06-01) -
Remuneration of community pharmaceutical services
by: Crealey, Grainne
Published: (1999) -
Current Trends and Challenges in Pharmacoeconomic Aspects of Nanocarriers as Drug Delivery Systems for Cancer Treatment
by: Milewska S, et al.
Published: (2021-09-01) -
The use of sugammadex for bariatric surgery: analysis of recovery time from neuromuscular blockade and possible economic impact
by: De Robertis E, et al.
Published: (2016-06-01) -
Pharmacoeconomic aspects of the diabetic ketoacidosis prevention in type 1 diabetes mellitus by self-monitoring of blood ketones
by: E. E. Petryaykina, et al.
Published: (2018-06-01)